Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1B | P28222 | 13/20 | 1.00 |
| ▸ | HTR1D | P28221 | 3/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.90 |
| ▸ | HRH1 | P35367 | 1/20 | 0.90 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.65 |
| ▸ | HPGD | P15428 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30756664 | 1.00 | HTR1B (1.00) | HTR1BHTR1DSLC6A4HRH1NR2E1 | |
| SCHEMBL3128162 | 0.95 | SLC6A4 (1.00) | HTR1BHTR1DSLC6A4HRH1NR2E1 | |
| SCHEMBL6852773 | 0.88 | SLC6A4 (0.97) | HTR1BHTR1DSLC6A4HRH1NR2E1 | |
| SCHEMBL23067892 | 0.85 | HTR1B (0.84) | HTR1BHTR1DSLC6A4HRH1NR2E1 | |
| SCHEMBL30756665 | 0.85 | HTR1B (0.84) | HTR1BHTR1DSLC6A4HRH1NR2E1 | |
| SCHEMBL7908960 | 0.82 | HTR1B (0.69) | HTR1BHTR1DSLC6A4HRH1KDM4E | |
| SCHEMBL5289923 | 0.82 | HTR1B (0.77) | HTR1BHTR1DSLC6A4HRH1NR2E1 | |
| SCHEMBL10923963 | 0.81 | HTR1B (1.00) | HTR1BHTR1DSLC6A4HRH1NR2E1 | |
| SCHEMBL8761450 | 0.81 | HTR1B (1.00) | HTR1BHTR1DSLC6A4HRH1NR2E1 | |
| SCHEMBL2177350 | 0.81 | HTR1B (0.78) | HTR1BHTR1DSLC6A4HRH1NR2E1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11896969-B2 | Anionic exchange-hydrophobic mixed mode chromatography resins | BIO-RAD LABORATORIES, INC. (US) | 2024-02-13 | — | — | US | claimed |
| US-11896969-B2 | Anionic exchange-hydrophobic mixed mode chromatography resins | BIO-RAD LABORATORIES, INC. (US) | 2024-02-13 | — | — | US | disclosed |
| US-20210069692-A1 | ANIONIC EXCHANGE-HYDROPHOBIC MIXED MODE CHROMATOGRAPHY RESINS | BIO-RAD LABORATORIES, INC. | 2021-03-11 | — | — | US | disclosed |
| US-20210069692-A1 | ANIONIC EXCHANGE-HYDROPHOBIC MIXED MODE CHROMATOGRAPHY RESINS | BIO-RAD LABORATORIES, INC. | 2021-03-11 | — | — | US | disclosed |
| US-6756384-B2 | TREATMENT OF DISEASES AND DISORDERS RELATED TO THE HISTAMINE H3 RECEPTOR. | NOVO NORDISK A/S (DK) | 2004-06-29 | — | — | US | disclosed |
| US-20030135056-A1 | Imidazole compounds | HIGH POINT PHARMACEUTICALS, LLC | 2003-07-17 | — | — | US | disclosed |
| US-6437147-B1 | FOR THERAPY OF DISEASES OF CENTRAL NERVOUS SYSTEM, PERIPHERAL NERVOUS SYSTEM, CARDIOVASCULAR SYSTEM, PULMONARY SYSTEM, GASTROINTESTINAL SYSTEM AND ENDOCRINOLOGICAL SYSTEM | NOVO NORDISK (DK) | 2002-08-20 | — | — | US | disclosed |
| US-20020058659-A1 | Imidazole compounds | HIGH POINT PHARMACEUTICALS, LLC | 2002-05-16 | — | — | US | disclosed |
| US-5986042-A | Cross-linked polymer | MITSUI CHEMICALS, INC. (JP) | 1999-11-16 | — | — | US | disclosed |
| EP-0856539-A1 | Cross-linked polymer | Mitsui Chemicals, Inc. (JP) | 1998-08-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030135056-A1 | Imidazole compounds | HRH3, HRH4, HRH2 | HTR1B 114/4885HTR1D 146/4885SLC6A4 841/4885 |
| US-20210069692-A1 | ANIONIC EXCHANGE-HYDROPHOBIC MIXED MODE CHROMATOGRAPHY RESINS | ABCG2, SLC7A1, MSR1 | HTR1B 1932/4885HTR1D 2519/4885SLC6A4 234/4885 |
| US-20020058659-A1 | Imidazole compounds | HRH3, HRH4, HRH2 | HTR1B 114/4885HTR1D 146/4885SLC6A4 841/4885 |
| US-11896969-B2 | Anionic exchange-hydrophobic mixed mode chromatography resins | ABCG2, SLC7A1, MSR1 | HTR1B 1932/4885HTR1D 2519/4885SLC6A4 234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.